ClinicalTrials.gg
RecruitingNCT07489885N/ZUpdated Jul 9, 2026

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of D-2570 Tablet and Placebo Tablets in Psoriasis, sponsored by InventisBio Co., Ltd. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by InventisBio Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
339th of 673
75 · median 77
Started
2026
with 15 others
Phase 2
200 of 764
5 open now
Primary completion
2027-08
later than 44 of 85 live
Registered
756th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 339th largest by planned enrollment of the 673 interventional ones that give a count, is one of 16 that started in 2026, is one of 200 in phase 2, reaches primary completion later than 44 of the 85 other live ones, and was the 756th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Read the detailed description

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Moderate to Severe Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the
  • Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
  • Within normal ranges of laboratory assessments

Exclusion criteria

Exclusion Criteria:

  • Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    D-2570 low dose

    Low dose of D-2570

    Drug: D-2570 Tablet

  • Active comparator
    D-2570 High Dose

    medium dose level of D-2570

    Drug: D-2570 Tablet

  • Placebo comparator
    Placebo

    Placebo arm

    Drug: Placebo Tablets

Interventions

  • Active Treatment

  • DrugPlacebo Tablets

    Identical Tablet

06

What researchers measure

Primary outcomes

  1. Improvement in PASI-90

    Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

    Time frame: Assessment completed after 12 weeks of treatment/placebo

07

Study locations

3 of 20 sites recruiting
  • Study Center
    Birmingham, Alabama 35244, United States
    Recruiting
  • Study Center
    Phoenix, Arizona 85008, United States
    Not yet recruiting
  • Study Center
    Chula Vista, California 91910, United States
    Recruiting
  • Study Center
    Fountain Valley, California 92708, United States
    Not yet recruiting
  • Study Center
    Fremont, California 94538, United States
    Not yet recruiting
  • Study Center
    Los Angeles, California 90017, United States
    Not yet recruiting
  • Study Center
    Los Angeles, California 90024, United States
    Not yet recruiting
  • Study Center
    San Diego, California 92123, United States
    Not yet recruiting
  • Study Center
    Fort Lauderdale, Florida 33308, United States
    Not yet recruiting
  • Study Center
    Miramar, Florida 33027, United States
    Not yet recruiting
  • Study Center
    Ocala, Florida 34470, United States
    Not yet recruiting
  • Study Center
    Tampa, Florida 33607, United States
    Not yet recruiting
  • Study Center
    Sandy Springs, Georgia 30328, United States
    Not yet recruiting
  • Study Center
    Savannah, Georgia 31419, United States
    Not yet recruiting
  • Study Center
    Idaho Falls, Idaho 83404, United States
    Not yet recruiting
  • Study Center
    Clarksville, Indiana 40241, United States
    Not yet recruiting
  • Study Center
    Louisville, Kentucky 40241, United States
    Not yet recruiting
  • Study Center
    Mayfield Heights, Ohio 44124, United States
    Not yet recruiting
  • Study Center
    Philadelphia, Pennsylvania 19103, United States
    Not yet recruiting
  • Study Center
    San Antonio, Texas 78218, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 14 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489885
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Jun 3, 2026
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Kathryn Stazzone
Contact
kathryn.stazzone@inventisbio.com
3025195966

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-2570

Start the discussion